title: Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey.
abstract: We present results of the second survey of the Italian Multicenter Study on Low-Density Lipoprotein Apheresis (IMSLDLa-WG/2). The study involved 18 centers in 2009, treating 66 males and 35 females, mean age 47 ± 18 years. Mean age for initiation of drug treatment before low-density lipoprotein apheresis (LDLa) was 31 ± 18 years, mean age to the first LDLa was 37 ± 20 years and average duration of treatment was 9 ± 6 years. The techniques used included direct adsorption of lipids, dextran sulfate cellulose adsorption, heparin-mediated low-density lipoprotein (LDL) precipitation, cascade filtration, and plasma exchange. The mean treated plasma/blood volumes/session were 3127 ± 518 mL and 8666 ± 1384 mL, respectively. The average plasma volume substituted was 3500 ± 300 mL. Lipid therapy before LDLa included ezetimibe, statins, ω-3 fatty acids and fenofibrate. Baseline mean LDL cholesterol (LDLC) levels were 386 ± 223 mg/dL. The mean before/after apheresis LDLC level decreased by 67% from 250 ± 108 mg/dL (P = 0.05 vs. baseline) to 83 ± 37 mg/dL (P = 0.001 vs. before). Baseline mean Lipoprotein(a) [Lp(a)] level was 179 ± 136 mg/dL. Mean before/after apheresis Lp(a) level decreased by 71% from 133 ± 120 mg/dL (P = 0.05 vs. baseline) to 39 ± 44 mg/dL (P = 0.001 vs. before). Major and minor side effects occurred in 27 and 62 patients, respectively. Among patients with coronary artery disease (CAD), 62.3% had coronary angiography and 50.4% coronary revascularization before LDLa. Single vessel, double vessel and triple vessel CAD occurred in 19 (30.1%), 15 (23.8%) and 29 (46%) patients, respectively. Both CAD and extra-CAD occurred in 41.5%, 39% had hypertension, 9.9% were smokers, 9.9% consumed alcohol and 42% were physically active. Ischemic cardiovascular events were not observed in any patient over 9 ± 6 years of treatment. Two centers have also treated 34 patients (females: 17/males 17; no. sessions: 36; average plasma volume treated: 3000 mL) for sudden hearing loss (SHL). Relief of symptoms was obtained, independently of the system used (HELP; cascade-filtration).
authors.affiliation: Department of Immunohematology and Transfusion Medicine, Extracorporeal Therapeutic Techniques Unit, University of Rome La Sapienza, Rome, Italy. cstefanutti@alice.it
authors.forename: Claudia
authors.initials: C
authors.lastname: Stefanutti
authors.forename: Claudia
authors.initials: C
authors.lastname: Morozzi
authors.forename: Serafina
authors.initials: S
authors.lastname: Di Giacomo
mesh_terms: D000328:Adult; D000368:Aged; D000428:Alcohol Drinking / Q000453:epidemiology; D001781:Blood Component Removal / Q000009:adverse effects / Q000379:methods*; D008078:Cholesterol, LDL / Q000097:blood*; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000503:physiopathology / Q000628:therapy; D050171:Dyslipidemias / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007558:Italy; D017270:Lipoprotein(a) / Q000097:blood; D008297:Male; D008875:Middle Aged; D012907:Smoking / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D008078:Cholesterol, LDL; D017270:Lipoprotein(a)